EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management

Paola Borgia iD, Gianluca Piccolo, Andrea Santangelo iD, Cristina Chelleri iD, Gianmaria Viglizzo, Corrado Occella, Carlo Minetti, Pasquale Striano iD, Maria Cristina Diana iD

Journal of Clinical Medicine · 20.03.2024 · 13 (6) · 1792

DOI: 10.3390/jcm13061792 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Medicine, online erschienen am 20.03.2024. Verfasst von Paola Borgia und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Pulmonology and Respiratory Endoscopy Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Plexiform neurofibromas (pNFs) are benign neoplasms, primarily originating from Schwann cells, posing challenges in patients with type 1 neurofibromatosis (NF1) due to pain, disfigurement, compression of vital structures and potential for malignancy. Selumetinib, a MEK1/2 inhibitor, has shown promising results in treating inoperable pNFs, with clinical trials demonstrating tumor volume reduction and improved patient-reported outcomes. Despite its efficacy, dermatologic toxicities may impact the quality of life and treatment adherence. Evaluating the frequency and spectrum of such effects is crucial for effective management.

Methods

In a four-year retrospective and prospective study, pediatric NF1 patients with symptomatic, inoperable plexiform neurofibromas (pNFs) were treated with selumetinib. Eligibility criteria included significant morbidity, pNF size exceeding 3 cm or surgical inoperability, and performance status >70%. Hematological, liver, lung and cardiac assessments established baseline health. Selumetinib, orally administered at 25 mg/m2 twice, was administered for two years unless a response warranting extension occurred. Cutaneous AEs were documented and graded by severity according to CTCAE v5.0, with evaluations every three to six months. The impact on symptoms and pNF size was systematically recorded, and biopsies characterized histopathological features in those patients requiring surgery.

Results

Twenty patients were enrolled, with an average age at therapy initiation of 11.6 years. Cutaneous side effects were common, with all patients experiencing at least one and a median of two per patient. Xerosis, paronychia and acneiform rash were prevalent. Notably, pre-pubertal individuals were more susceptible to xerosis. Acneiform rash had a higher incidence in older patients and those with skin phototypes II and III. Successful management involved tailored approaches, such as clindamycin for acneiform rash and topical agents for paronychia. Hair abnormalities, including color changes and thinning, occurred, with female patients at higher risk for the latter. Paronychia presented challenges, necessitating various interventions, including surgical approaches. AEs led to treatment suspension in 20% of patients, with tumor rebound observed in 75%.

Conclusions

According to our experience, successful management of selumetinib-induced cutaneous AEs requires tailored strategies including surgery. AEs might indirectly determine pNF regrowth due to therapy suspension. We thus emphasize the pivotal role of addressing cutaneous reactions for effective selumetinib management in pediatric patients.

Schlagwörter

Stichwörter der Autor:innen

NF1managementneurofibromatosis type 1pediatric dermatologyplexiform neurofibromaspreventionselumetinib

Autor:innen und Institutionen

  • Pediatric Pulmonology and Respiratory Endoscopy Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.
  • Neuro-Oncology Unit, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.
  • Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, University of Genoa, 16126 Genova, Italy.
  • Pediatric Neurology, Pediatric Department, AOUP Santa Chiara Hospital, 56100 Pisa, Italy.
  • Dermatology and Angioma Center, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.
  • Pediatric Neurology and Muscular Diseases Unit, Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy.

ORCID-Profile: Paola Borgia, Andrea Santangelo, Cristina Chelleri, Pasquale Striano, Maria Cristina Diana

Zitieren

APA

Borgia, P., Piccolo, G., Santangelo, A., Chelleri, C., Viglizzo, G., Occella, C., Minetti, C., Striano, P., & Diana, M. C. (2024). Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management. Journal of Clinical Medicine, 13(6), 1792. https://doi.org/10.3390/jcm13061792

Vancouver

Borgia P, Piccolo G, Santangelo A, Chelleri C, Viglizzo G, Occella C, et al. Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management. Journal of Clinical Medicine. 2024;13(6):1792. doi:10.3390/jcm13061792

BibTeX
@article{Borgia2024,
  author = {Borgia, Paola and Piccolo, Gianluca and Santangelo, Andrea and Chelleri, Cristina and Viglizzo, Gianmaria and Occella, Corrado and Minetti, Carlo and Striano, Pasquale and Diana, Maria Cristina},
  title = {Dermatologic Effects of Selumetinib in Pediatric Patients with Neurofibromatosis Type 1: Clinical Challenges and Therapeutic Management},
  journal = {Journal of Clinical Medicine},
  year = {2024},
  volume = {13},
  number = {6},
  pages = {1792},
  doi = {10.3390/jcm13061792}
}
Kostenlos starten →